Skip to main content
SpringerLink
Log in

Radiotherapy appears to be most cost-effective option for standard-risk DCIS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gupta A, et al. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal of Clinical Oncology : JCO2100831, 12 May 2021. Available from: URL: http://doi.org/10.1200/JCO.21.00831

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Radiotherapy appears to be most cost-effective option for standard-risk DCIS. PharmacoEcon Outcomes News 880, 25 (2021). https://doi.org/10.1007/s40274-021-7783-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7783-z

Search

Navigation